Recent studies have highlighted the role of mitochondrial calcium uniporters (MCU) in mediating iron-induced mitochondrial dysfunction
Naturally, when a B12 deficiency is suspected or diagnosed, the next question often arises: whats the best way to get it back on track
Alpha Lipoic Acid is a great promoter of intracellular glutathione
Berberine Protects Immortalized Line of Human Melanocytes from H2O2-Induced Oxidative Stress via Activation of Nrf2 and Mitf Signaling Pathway
Knowing about cyanocobalamins safety helps doctors and patients
Key Takeaways Cagrilintide is a long-acting amylin analogue typically dosed at 2.4 mg weekly in clinical trials, working through distinct pathways from GLP-1 receptor agonists Tirzepatide follows a gradual escalation protocol from 2.5 mg to 15 mg weekly as a dual GIP/GLP-1 receptor agonist No approved combination of cagrilintide with tirzepatide currently exists, though the concept represents theoretical triple-pathway metabolic modulation Gastrointestinal side effects require careful monitoring when considering any combination of these peptides due to overlapping mechanisms Clinical evidence for cagrilintide combinations exists primarily with semaglutide, showing 15-17% body weight reductions in phase 3 trials Understanding Cagrilintide: The Amylin Analogue Cagrilintide represents a breakthrough in amylin-based therapeutics, developed by Novo Nordisk as a long-acting analogue of the naturally occurring hormone amylin[1]